<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874249</url>
  </required_header>
  <id_info>
    <org_study_id>FAFLD</org_study_id>
    <nct_id>NCT01874249</nct_id>
  </id_info>
  <brief_title>Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease</brief_title>
  <official_title>Randomized Clinical Trial to Detect Advanced Fibrosis by Non-invasive Methods in Subjects With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Clínica Médica Sur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Clínica Médica Sur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized clinical trial is to evaluate the utility of noninvasive
      markers for the detection of advanced fibrosis in patients newly diagnosed with Non-alcoholic
      Fatty Liver Disease (NAFLD) by ultrasound.

      The primary objective is to determine the effectiveness of noninvasive markers for detect of
      advanced fibrosis in patients with diagnosis of fatty liver disease.

      The secondary objectives are:

        -  To determine the increase in health care with the specialist (gastroenterologist or
           endocrinologist).

        -  To determine which noninvasive evaluation strategy favors any treatment of fatty liver
           disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Advanced Fibrosis by any diagnostic modality</measure>
    <time_frame>One year after the diagnosis of steatosis.</time_frame>
    <description>Evidence of advanced fibrosis, diagnosed by transient elastography (greater than 8 kPa), NAFLD Score above 0.675, liver biopsy or any other non-invasive marker of liver fibrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specialized care</measure>
    <time_frame>One year after the diagnosis of steatosis.</time_frame>
    <description>Through telephone follow-up, investigate if the patient attends to gastroenterologist or endocrinologist for examination, diagnostic confirmation or any treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Electronic detailed information</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD Score</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD Score plus Transient elastography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transient elastography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care for patients with diagnosis of fatty liver by ultrasound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic detailed information</intervention_name>
    <description>Electronic detailed information about non alcoholic fatty liver disease.</description>
    <arm_group_label>Electronic detailed information</arm_group_label>
    <arm_group_label>NAFLD Score</arm_group_label>
    <arm_group_label>NAFLD Score plus Transient elastography</arm_group_label>
    <arm_group_label>Transient elastography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NAFLD Score</intervention_name>
    <description>diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854</description>
    <arm_group_label>NAFLD Score</arm_group_label>
    <arm_group_label>NAFLD Score plus Transient elastography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transient elastography</intervention_name>
    <description>Transient elastography values greater than 8 kPa</description>
    <arm_group_label>NAFLD Score plus Transient elastography</arm_group_label>
    <arm_group_label>Transient elastography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with BMI ≥ 27 Kg/m2 and any stage of non alcoholic fatty liver, diagnosed by
             ultrasound.

        Exclusion Criteria:

          -  Patients with other liver disease.

          -  Patients under treatment with tamoxifen, methotrexate, amiodarone, diltiazem or other
             drugs able to induce fatty liver.

          -  Patients with alcohol consumption greater than 140 gr. per week

          -  Patients who have received blood transfusion before 1990
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medica Sur Clinic &amp; Foundation</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Clínica Médica Sur</investigator_affiliation>
    <investigator_full_name>Norberto Carlos Chavez Taia</investigator_full_name>
    <investigator_title>Norberto Carlos Chavez-Tapia</investigator_title>
  </responsible_party>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>Steatosis</keyword>
  <keyword>Noninvasive markers.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

